Business
Research Reports Initiated on Healthcare Stocks Resverlogix, Immunovaccine, IntelliPharmaCeutics International, and Aeterna Zentaris
LONDON, UK / ACCESSWIRE / February 24, 2017 / Active Wall St. announces the list of stocks f...
About this update from Cosciens Biopharma Inc.
[{"type":"text","content":"Research Reports Initiated on Healthcare Stocks Resverlogix, Immunovaccine, IntelliPharmaCeutics International, and Aeterna ZentarisLONDON, UK / ACCESSWIRE / February 24, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Biotechnology industry. Companies recently under review include Resverlogix, Immunovaccine, IntelliPharmaCeutics International, and Aeterna Zentaris. Get all of our free research reports by signing up at:\nhttp://www.activewallst.com/register/\nAt the close of the Canadian markets on Thursday, February 23, 2017, the Toronto Exchange Composite index ended the trading session at 15,781.20, 0.31% lower from its previous closing price.\nThe Healthcare Index was also in the red, closing the day at 75.83, down 0.66%.\nActive Wall St. has initiated research reports on the following equities: Resverlogix Corporation (TSX: RVX), Immunovaccine Inc. (TSX: IMV), IntelliPharmaCeutics International Inc. (TSX: I), and Aeterna Zentaris Inc. (TSX: AEZ). Register with us now for your free membership and research reports at:\nhttp://www.activewallst.com/register/\nResverlogix Corp.\nCalgary, Canada headquartered Resverlogix Corp.'s stock closed the day 3.21% higher at $1.93. The stock recorded a trading volume of 27,554 shares. Resverlogix's shares have gained 6.63% in the last three months and 27.81% in the past one year. Shares of the company, which develops small molecule therapeutics for Bromodomain and ExtraTerminal inhibition, are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $1.86 is greater than its 200-day moving average of $1.74. See our research report on RVX.TO at:\nhttp://www.activewallst.com/register/\nImmunovaccine Inc.\nHalifax, Canada headquartered Immunovaccine Inc.'s stock fell 2.38%, to finish Thursday's session at $1.23 with a total volume of 105,459 shares traded. Over the last one month and the previous three months, Immunovaccine's shares have surged 80.88% and 53.75%, respectively. Furthermore, the stock has rallied 156.25% in the past one year. Shares of the company, which develops products based on its proprietary vaccine enhancement platform with a primary focus on T c...